CClinicalTrials.gg
Enrolling by invitationNCT07779551Updated Aug 21, 2026

Comparison of Two Drugs Bupivacaine and Ropivacaine for Postoperative Analgesia in Bilateral Superficial Cervical Plexus Block After Thyroidectomy

An interventional study of Group 1 will receive 10ml of 0.25% bupivacaine and Group 2 will receive 10ml of 0.25% ropivacaine on each side. in Postoperative Pain, sponsored by Sargodha Medical College. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Sargodha Medical College · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Study summary

There is significant difference between bupivacaine and ropivacaine in terms of postoperative pain assessment in patients undergoing total thyroidectomy with bilateral superficial cervical plexus block.

02

Conditions studied

  • Postoperative Pain

Browse trials for

03

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Age range:20-40 years.
  2. Both male and female individuals.
  3. Patients classified as American Society of Anesthesiologists (ASA)I-II.
  4. Patients scheduled for elective total thyroidectomy under general anesthesia

Exclusion criteria

Exclusion Criteria:

  1. Patient Refusal
  2. Hypothyroidism,Hyperthyroidism,Retrosternal goiter
  3. Premedication with preoperative analgesics
  4. Excessive alcohol intake,Electrolyte imbalance
  5. Pregnancy or lactation
  6. Coagulation disorders
  7. Additional surgical intervention
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
94 participants (estimated)

Study arms

  • Other
    Group 1 will receive 10ml of 0.25% bupivacaine on each side,

    Procedure: Group 1 will receive 10ml of 0.25% bupivacaine

  • Other
    Group 2 will receive 10ml of 0.25% ropivacaine on each side

    Procedure: Group 2 will receive 10ml of 0.25% ropivacaine on each side.

Interventions

  • ProcedureGroup 1 will receive 10ml of 0.25% bupivacaine

    After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure.

  • ProcedureGroup 2 will receive 10ml of 0.25% ropivacaine on each side.

    After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure

05

What researchers measure

Primary outcomes

  1. Postoperative pain

    Time frame: 24 hours post surgery

  2. time to the first request for analgesia

    Time frame: 24 hours postoperatively

  3. Block-related complications

    Time frame: immediately after the intervention/procedure

06

Study locations

1 site
  • Dr Faisal Masood teaching Hospital Sargodha
    Sargodha, Punjab Province 40100, Pakistan
07

Registry details

Key details

Study ID
NCT07779551
Lead sponsor
Sargodha Medical College
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Jan 22, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion